1.Wang S, Liu X, Qiao T, Zhang Q: Radiosensitization by CpG ODN7909 in an epidermoid laryngeal carcinoma Hep–2 cell line. Journal of International Medical Research 2017, 45(6):2009–2022.
2.Uloza V, Ulozaite N, Vaitkus S, Sarauskas V: Spontaneous regression of laryngeal carcinoma in 10 year old boy: a case report and review of literature. International journal of pediatric otorhinolaryngology 2017, 103:10–13.
3.Chen L, Jin M, Li C, Shang Y, Zhang Q: The tissue distribution and significance of B7-H4 in laryngeal carcinoma. Oncotarget 2017, 8(54):92227.
4.Si F, Feng Y, Han M: Association between interleukin–17 gene polymorphisms and the risk of laryngeal cancer in a Chinese population. Genetics and molecular research: GMR 2017, 16(1).
5.Tang WJ, Tao L, Lu LM, Tang D, Shi XL: Role of T helper 17 cytokines in the tumour immune inflammation response of patients with laryngeal squamous cell carcinoma. Oncology letters 2017, 14(1):561–568.
6.Kopta R, Mochocki M, Morawski P, Brzezińska-Błaszczyk E, Lewy-Trenda I, Circle SS, Starska K: Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma–Preliminary study. Contemporary Oncology 2015, 19(3):195.
7.Chen L, Shan K, Wu P, Yan Z, Wang W: Alteration of IFN-γ, IL–4, IL–17 and TGF-β levels in Serum of Patients with Chronic Lymphocytic Leukemia Treated with FCR. Zhongguo shi yan xue ye xue za zhi 2017, 25(6):1615–1620.
8.Xue J, Wang Y, Chen C, Zhu X, Zhu H, Hu Y: Effects of Th17 cells and IL‐17 in the progression of cervical carcinogenesis with high‐risk human papillomavirus infection. Cancer medicine 2018, 7(2):297–306.
9.Ibrahim S, Girault A, Ohresser M, Lereclus E, Paintaud G, Lecomte T, Raoul W: Monoclonal antibodies targeting the IL–17/IL–17RA axis: an opportunity to improve the efficiency of anti-VEGF therapy in fighting metastatic colorectal cancer? Clinical colorectal cancer 2018, 17(1):e109-e113.
10.Varikuti S, Oghumu S, Elbaz M, Volpedo G, Ahirwar DK, Alarcon PC, Sperling RH, Moretti E, Pioso MS, Kimble J: STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL–17 blockade. Oncoimmunology 2017, 6(11):e1361088.
11.Amara S, Majors C, Roy B, Hill S, Rose KL, Myles EL, Tiriveedhi V: Critical role of SIK3 in mediating high salt and IL–17 synergy leading to breast cancer cell proliferation. PloS one 2017, 12(6):e0180097.
12.Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirstrom K, Leandersson K: Infiltration of gammadelta T cells, IL–17+ T cells and FoxP3+ T cells in human breast cancer. Cancer biomarkers: section A of Disease markers 2017, 20(4):395–409.
13.Song Y, Yang JM: Role of interleukin (IL)–17 and T-helper (Th) 17 cells in cancer. Biochemical and biophysical research communications 2017, 493(1):1–8.
14.Yang L, Liu H, Zhang L, Hu J, Chen H, Wang L, Yin X, Li Q, Qi Y: Effect of IL–17 in the development of colon cancer in mice. Oncology letters 2016, 12(6):4929–4936.
15.Liu Y, Yang W, Zhao L, Liang Z, Shen W, Hou Q, Wang Z, Jiang J, Ying S: Immune analysis of expression of IL–17 relative ligands and their receptors in bladder cancer: comparison with polyp and cystitis. BMC immunology 2016, 17(1):36.
16.Mohammadi M, Kaghazian M, Rahmani O, Ahmadi K, Hatami E, Ziari K, Talebreza A: RETRACTED ARTICLE: Overexpression of interleukins IL–17 and IL–8 with poor prognosis in colorectal cancer induces metastasis. Tumor Biology 2016, 37(6):7501–7505.
17.Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R: Targeting the tumor microenvironment: the protumor effects of IL–17 related to cancer type. International journal of molecular sciences 2016, 17(9):1433.
18.Cui J, Wei C, Deng L, Kuang X, Zhang Z, Pierides C, Chi J, Wang L: MicroRNA‑143 increases cell apoptosis in myelodysplastic syndrome through the Fas/FasL pathway both in vitro and in vivo. International journal of oncology 2018, 53(5):2191–2199.
19.Murinello S, Usui Y, Sakimoto S, Kitano M, Aguilar E, Friedlander HM, Schricker A, Wittgrove C, Wakabayashi Y, Dorrell MI: miR‐30a‐5p inhibition promotes interaction of Fas+ endothelial cells and FasL+ microglia to decrease pathological neovascularization and promote physiological angiogenesis. Glia 2019.
20.Weidinger C, Krause K, Mueller K, Klagge A, Fuhrer D: FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. The Journal of Clinical Endocrinology & Metabolism 2011, 96(9):E1361-E1371.
21.Lim SW, Jin L, Luo K, Jin J, Shin YJ, Hong SY, Yang CW: Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. Cell death & disease 2017, 8(8):e2972.
22.Sampattavanich S, Steiert B, Kramer BA, Gyori BM, Albeck JG, Sorger PK: Encoding Growth Factor Identity in the Temporal Dynamics of FOXO3 under the Combinatorial Control of ERK and AKT Kinases. Cell systems 2018, 6(6):664–678. e669.
23.Park SH, Lee J, Kang M, Jang KY, Kim JR: Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. Oncology letters 2018, 15(6):9687–9696.
24.Zhang B-f, Hu Y, Liu X, Cheng Z, Lei Y, Liu Y, Zhao X, Mu M, Yu L, Cheng M-l: The role of AKT and FOXO3 in preventing ovarian toxicity induced by cyclophosphamide. PloS one 2018, 13(8):e0201136.
25.Wu S-X, Chen W-N, Jing Z-T, Liu W, Lin X-J, Lin X: Hepatitis B spliced protein (HBSP) suppresses Fas-mediated hepatocyte apoptosis via activation of PI3K/Akt signaling. Journal of virology 2018, 92(23):e01273–01218.
26.Zhu L, Derijard B, Chakrabandhu K, Wang B-S, Chen H-Z, Hueber A-O: Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. Cancer letters 2014, 354(2):355–364.
27.Mitrović S, Kelava T, Šućur A, Grčević D: Levels of selected aqueous humor mediators (IL–10, IL–17, CCL2, VEGF, FasL) in diabetic cataract. Ocular immunology and inflammation 2016, 24(2):159–166.
28.Bień K, Żmigrodzka M, Orłowski P, Fruba A, Szymański Ł, Stankiewicz W, Nowak Z, Malewski T, Krzyżowska M: Involvement of Fas/FasL pathway in the murine model of atopic dermatitis. Inflammation Research 2017, 66(8):679–690.
29.Ma H, Lian R, Wu Z, Li X, Yu W, Shang Y, Guo X: MiR–503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1. Tumor Biology 2017, 39(10):1010428317706224.
30.Yener HM, Yilmaz M, Karaaltin AB, Inan HC, Turgut F, Gozen ED, Comunoglu N, Karaman E: The incidence of thyroid cartilage invasion in early-stage laryngeal carcinoma: Our experience on sixty-two patients. Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2018, 43(1):388–392.
31.Topuz MF, Binnetoglu A, Yumusakhuylu AC, Sari M, Baglam T, Gerin F: Circulating calprotectin as a biomarker of laryngeal carcinoma. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2017, 274(6):2499–2504.
32.El Tabbakh MT, Ahmed MR: The role of sentinel lymph node biopsy in the management of laryngeal carcinoma. 2017, 42(5):1069–1072.
33.Tao Y, Tao T, Gross N, Peng X, Li Y, Huang Z, Liu L, Li G, Chen X, Yang J: Combined Effect of IL–12Rbeta2 and IL–23R Expression on Prognosis of Patients with Laryngeal Cancer. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2018, 50(3):1041–1054.
34.Tao Y, Gross N, Fan X, Yang J, Teng M, Li X, Li G, Zhang Y, Huang Z: Identification of novel enriched recurrent chimeric COL7A1-UCN2 in human laryngeal cancer samples using deep sequencing. BMC cancer 2018, 18(1):248.
35.Wang Y, Yang J, Xu H: Expression of IL–17 in laryngeal squamous cell carcinoma tissues and the clinical significance. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 2013, 27(14):779–783.
36.Li F-J, Cai Z-J, Yang F, Zhang S-D, Chen M: Th17 expression and IL–17 levels in laryngeal squamous cell carcinoma patients. Acta oto-laryngologica 2016, 136(5):484–490.
37.Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J: Growth differentiation factor (GDF–15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer Biomarkers 2018(Preprint):1–7.
38.Yang J, Kim Y-K, Kang TS, Jee Y-K, Kim Y-Y: Importance of indoor dust biological ultrafine particles in the pathogenesis of chronic inflammatory lung diseases. Environmental health and toxicology 2017, 32.
39.Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N: Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. Anticancer research 2018, 38(1):553–557.
40.Ohkubo T, Midorikawa Y, Nakayama H, Moriguchi M, Aramaki O, Yamazaki S, Higaki T, Takayama T: Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors. Hepatology Research 2018, 48(6):433–441.
41.Chien J, Poole EM: Ovarian cancer prevention, screening, and early detection: Report from the 11th biennial ovarian cancer research symposium. International Journal of Gynecologic Cancer 2017, 27(S5):S20-S22.
42.Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M: Malignancy risk and recurrence with psoriasis and its treatments: a concise update. American journal of clinical dermatology 2018, 19(3):363–375.
43.Son H-Y, Apostolopoulos V, Kim C-W: Mannosylated T/Tn with Freund’s adjuvant induces cellular immunity. International journal of immunopathology and pharmacology 2018, 31:0394632017742504.
44.Sánchez-Bretaño A, Baba K, Janjua U, Piano I, Gargini C, Tosini G: Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase–3. Molecular vision 2017, 23:844.
45.Sun H, Liu Y, Bu D, Liu X, Norris JS, Xiao S: Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP‐2 induced by an adeno‐associated virus expressing human FAS ligand. Head & neck 2012, 34(11):1628–1633.
46.Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466(7308):835.
47.Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y, Ren J: Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cellular and Molecular Life Sciences 2019:1–11.
48.Dieci G, Fiorino G, Castelnuovo M, Teichmann M, Pagano A: The expanding RNA polymerase III transcriptome. TRENDS in Genetics 2007, 23(12):614–622.
49.Dong P, Zhang X, Zhao J, Li D, Li L, Yang B: Anti-microRNA–132 causes sevoflurane‑induced neuronal apoptosis via the PI3K/AKT/FOXO3a pathway. International journal of molecular medicine 2018, 42(6):3238–3246.
50.Lin F, Yang J, Muhammad U, Sun J, Huang Z, Li W, Lv F, Lu Z: Bacillomycin D-C16 triggers apoptosis of gastric cancer cells through the PI3K/Akt and FoxO3a signaling pathways. Anti-cancer drugs 2019, 30(1):46–55.
51.Pfaff CM, Marquardt Y, Fietkau K, Baron JM, Luscher B: The psoriasis-associated IL–17A induces and cooperates with IL–36 cytokines to control keratinocyte differentiation and function. Scientific reports 2017, 7(1):15631.
52.Li HJ, Wu NL, Lee GA, Hung CF: The Therapeutic Potential and Molecular Mechanism of Isoflavone Extract against Psoriasis. Scientific reports 2018, 8(1):6335.
53.Muhammad IF, Borne Y, Melander O, Orho-Melander M, Nilsson J, Soderholm M, Engstrom G: FADD (Fas-Associated Protein With Death Domain), Caspase–3, and Caspase–8 and Incidence of Ischemic Stroke. Stroke 2018, 49(9):2224–2226.
54.Wu X, Ragupathi G, Panageas K, Hong F, Livingston PO: Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway. Clinical cancer research: an official journal of the American Association for Cancer Research 2013, 19(17):4728–4739.
55.Szumlinski KK, Ary AW, Shin CB, Wroten MG, Courson J, Miller BW, Ruppert-Majer M, Hiller JW, Shahin JR, Ben-Shahar O et al: PI3K activation within ventromedial prefrontal cortex regulates the expression of drug-seeking in two rodent species. Addiction biology 2018.
56.Du P, Li SJ, Ojcius DM, Li KX, Hu WL, Lin X, Sun AH, Yan J: A novel Fas-binding outer membrane protein and lipopolysaccharide of Leptospira interrogans induce macrophage apoptosis through the Fas/FasL-caspase–8/–3 pathway. 2018, 7(1):135.
57.Svandova EB, Vesela B, Lesot H, Poliard A, Matalova E: Expression of Fas, FasL, caspase–8 and other factors of the extrinsic apoptotic pathway during the onset of interdigital tissue elimination. Histochemistry and cell biology 2017, 147(4):497–510.
58.Sobrido-Camean D, Barreiro-Iglesias A: Role of Caspase–8 and Fas in Cell Death After Spinal Cord Injury. Frontiers in molecular neuroscience 2018, 11:101.
59.Tanner SM, Daft JG, Hill SA, Martin CA, Lorenz RG: Altered T-Cell Balance in Lymphoid Organs of a Mouse Model of Colorectal Cancer. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 2016, 64(12):753–767.
60.Huang Q, Duan L, Qian X, Fan J, Lv Z, Zhang X, Han J, Wu F, Guo M, Hu G et al: IL–17 Promotes Angiogenic Factors IL–6, IL–8, and Vegf Production via Stat1 in Lung Adenocarcinoma. Scientific reports 2016, 6:36551.